Related Experiment Videos
Primary brain lymphomas in patients with a prior or concomitant malignancy
M Reni1, A J Ferreri, M C Zoldan
1Department of Radiochemotherapy, San Raffaele H Scientific Institute, Milan, Italy.
Journal of Neuro-Oncology
|April 1, 1997
Summary
Diagnosing a new brain tumor in cancer survivors is challenging. Primary central nervous system lymphomas (PCNSL) as a second malignancy require distinct treatment strategies for a potentially curative outcome.
Area of Science:
- Neuro-oncology
- Oncology
- Pathology
Background:
- Cancer survivors face an increased risk of developing second malignancies.
- Differentiating metastatic brain lesions from new primary brain tumors is diagnostically challenging.
- Primary central nervous system lymphomas (PCNSL) can occur as a second malignancy in approximately 8% of cases.
Observation:
- Brain lesions in cancer survivors necessitate careful differential diagnosis.
- Specific imaging characteristics (intense enhancement, deep location) and response to corticosteroids suggest PCNSL.
- PCNSL diagnosis significantly alters therapeutic management and prognosis compared to brain metastases.
Findings:
- Four cases of PCNSL as a second malignancy are presented.
- Literature review supports the distinct nature of PCNSL and brain metastases.
- Prompt diagnosis of PCNSL is crucial for appropriate treatment initiation.
Implications:
- Accurate diagnosis of PCNSL in cancer survivors can lead to curative treatment strategies.
- Distinguishing PCNSL from metastatic disease impacts patient prognosis and management goals.
- This distinction is critical as PCNSL treatment aims for cure, unlike the often palliative approach for brain metastases.